Cardiac Glycosides Inhibit TGF-beta Fibronectin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for activated fibroblast-associated diseases, such as cancer and fibrotic diseases, are inadequate in efficacy and some are toxic, with no effective therapies targeting cancer-associated fibroblasts (CAFs) that contribute to tumor progression and metastasis, and limited options for fibrotic diseases affecting organs like the lung and kidney.
Innovation Solution
Identification of compounds, particularly cardiac glycosides like digoxin, that inhibit CAF differentiation by blocking Transforming Growth Factor Beta 1 (TGF-β)-induced fibronectin production, using high-content imaging to screen drug libraries, which can be used alone or in combination with standard treatments to enhance anti-tumor efficacy and treat fibrotic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current medications are used to treat activated fibroblast-associated diseases, then treatment coverage is provided, but efficacy is inadequate and toxicity occurs
Solution Approach 1:
The patent extracts and isolates the specific pathological mechanism of TGF-β signaling in fibroblast activation from the complex disease process. By targeting this specific pathway with selective inhibitors rather than broad-spectrum treatments, the invention achieves effective fibroblast modulation without the systemic toxicity of conventional therapies.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediary substances that block the TGF-β signaling pathway. These intermediaries specifically interfere with the pathological communication between TGF-β and fibroblasts, preventing harmful fibroblast activation while sparing other physiological processes.
2Reliability
If no therapies target cancer-associated fibroblasts, then tumor progression continues, but new therapeutic targets remain unexplored
Solution Approach 1:
The patent segments the tumor microenvironment into distinct functional components, specifically identifying cancer-associated fibroblasts as a separable therapeutic target. By developing agents that selectively modulate CAFs independent of tumor cells themselves, the invention creates a new dimension for anti-tumor therapy that addresses the stromal component of cancer progression.
Solution Approach 2:
The patent develops TGF-β pathway inhibitors with universal applicability across multiple fibroblast-associated diseases including cancer, pulmonary fibrosis, and other fibrotic conditions. This multi-functional approach allows a single therapeutic mechanism to address diverse pathologies driven by fibroblast activation.
3Ease of operation
If limited drug options are available for fibrotic diseases, then treatment accessibility is maintained, but therapeutic effectiveness is reduced
Solution Approach 1:
The patent modifies the therapeutic parameter space by introducing small molecule inhibitors with distinct mechanisms of action targeting the TGF-β pathway. These novel agents expand the available therapeutic options beyond existing limited drugs, providing both accessibility through oral administration and effectiveness through pathway-specific inhibition.
Data Source
AI summary
A method of treating an activated fibroblast associated disease or pre-disease condition in a mammal comprising, administering a pharmaceutical composition including a therapeutically effective amount of a first therapeutic, wherein the first therapeutic is one of an intracellular Ca2+ elevator, a YAP/TAZ inhibitor, both a intracellular Ca2+ elevator and a YAP/TAZ inhibitor, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.